Europe - Euronext Brussels - EBR:OXUR - BE0974487192 - Common Stock
Taking everything into account, OXUR scores 2 out of 10 in our fundamental rating. OXUR was compared to 85 industry peers in the Biotechnology industry. OXUR has a bad profitability rating. Also its financial health evaluation is rather negative. OXUR has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 39.34% | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 45050% | ||
| PM (TTM) | 97950% | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.36 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.17 | ||
| Quick Ratio | 0.17 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.01 | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.62 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 2 / 10 to OXUR.BR.
ChartMill assigns a valuation rating of 3 / 10 to OXURION NV (OXUR.BR). This can be considered as Overvalued.
OXURION NV (OXUR.BR) has a profitability rating of 3 / 10.
The financial health rating of OXURION NV (OXUR.BR) is 0 / 10.